-
-
-
-
-
-
-
Celldex to present mast cell targeting drug data at European congress
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Celldex Therapeutics (CLDX) After Q3 Update
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Celldex Therapeutics (CLDX)
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Celldex Therapeutics (CLDX)
-
-
-
-
-
-
-
Morgan Stanley Starts Celldex Therapeutics (CLDX) at Overweight
-
-
-
-
-
-
-
Citi on Celldex Therapeutics (CLDX): 'Competitor CSU Data Unclear Under the Surface; Positive Readthrough for Celldex'
-
-
-
-
-
-
-
Goldman Sachs Starts Celldex Therapeutics (CLDX) at Neutral
-
434,570 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

